GRCE.NASDAQGrace Therapeutics, INC
10-Q: Acasti Pharma Reports Q3 2024 Results, Focuses on GTX-104 Clinical Trial
Sentiment:
Quarterly Report
Acasti Pharma's Q3 2024 report highlights a strategic shift towards its lead drug candidate, GTX-104, and a reduction in operating expenses.
Capital raiseThe company completed a private placement in September 2023, raising net proceeds of approximately $7.3 million.The company issued 1,951,371 Common Shares and pre-funded warrants to purchase up to 2,106,853 Common Shares.The company also issued common warrants to purchase up to 2,536,391 Common Shares.The company plans to raise additional capital in order to maintain adequate liquidity.
Better than expectedThe company's net loss decreased significantly compared to the same period in the previous year, indicating improved financial performance.Research and development expenses decreased substantially due to a strategic realignment, suggesting better cost management.The company successfully raised $7.3 million through a private placement, strengthening its financial position.
Summary
- Acasti Pharma reported a net loss of $2.39 million for the three months ended December 31, 2023, a decrease from a net loss of $3.89 million for the same period in 2022.
- The company's net loss for the nine months ended December 31, 2023, was $9.69 million, compared to a net loss of $13.34 million for the same period in 2022.
- Research and development expenses decreased to $2.998 million for the nine months ended December 31, 2023, from $8.332 million in the same period of 2022, due to a strategic realignment.
- The company completed a private placement in September 2023, raising net proceeds of approximately $7.3 million.
- Acasti's cash runway is expected to fund operations into the second calendar quarter of 2026.
- The company is prioritizing the development of GTX-104, a novel intravenous formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH).
- The first patient was enrolled in the Phase 3 safety trial for GTX-104 in October 2023, with the trial expected to take approximately 18 months to complete.
- The company has de-prioritized the development of GTX-102 and GTX-101, with further development contingent on additional funding or strategic partnerships.
Sentiment
Score: 7
Explanation: The document shows a positive shift in the company's strategy and financial position, with a clear focus on GTX-104 and reduced operating expenses. However, the company still faces risks and will need to raise additional capital in the future.
Positives
- The company has significantly reduced its net loss compared to the previous year.
- The strategic realignment has led to a substantial decrease in research and development expenses.
- The successful private placement has strengthened the company's financial position.
- The enrollment of the first patient in the Phase 3 trial for GTX-104 is a significant milestone.
- The company has a clear focus on its lead drug candidate, GTX-104.
- The company has extended its cash runway into the second quarter of 2026.
Negatives
- The company continues to incur operating losses and negative cash flows.
- The development of GTX-102 and GTX-101 has been deprioritized, potentially delaying their commercialization.
- The company is dependent on the success of its lead drug candidate, GTX-104.
- The company will require additional capital to fund its operations beyond the second quarter of 2026.
Risks
- The company is heavily dependent on the success of its lead drug candidate, GTX-104.
- Clinical development is a lengthy and expensive process with an uncertain outcome.
- The company is subject to uncertainty relating to healthcare reform measures and reimbursement policies.
- The company may be unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell its drug products.
- The company may be unable to differentiate its drug products from branded reference drugs or existing generic therapies.
- The company does not have internal manufacturing capabilities and relies on third-party manufacturers.
- The company may not be able to raise additional funds when needed.
Future Outlook
The company believes its cash runway will be sufficient to fund operations into the second calendar quarter of 2026. The company plans to raise additional capital to maintain adequate liquidity and is focused on advancing GTX-104 through its Phase 3 clinical trial. Further development of GTX-102 and GTX-101 will occur at such time when the Company is able to secure additional funding, or enters into strategic partnerships for license or sale with third parties.
Management Comments
- The Corporation believes its cash runway, including net proceeds from this financing, will be sufficient to fund the Corporations operations into the second calendar quarter of 2026.
- The Corporation plans to raise additional capital in order to maintain adequate liquidity.
- We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies.
- We believe that rare disorders represent an attractive area for drug development, and there remains an opportunity for us to utilize already approved drugs that have established safety profiles and clinical experience to potentially address significant unmet medical needs.
Industry Context
Acasti Pharma is operating in the biopharmaceutical industry, focusing on rare and orphan diseases. The company's strategy of repurposing existing drugs using novel delivery technologies aligns with a trend in the industry to find faster and more cost-effective paths to drug development. The focus on GTX-104 for aSAH addresses a significant unmet medical need, as current treatments have limitations. The company's decision to prioritize GTX-104 reflects a common strategy in the industry to focus resources on the most promising assets.
Comparison to Industry Standards
- Acasti's focus on a 505(b)(2) regulatory pathway is a common strategy for companies developing reformulated drugs, aiming for a faster approval process compared to new chemical entities.
- The company's decision to prioritize GTX-104 and de-prioritize other assets is similar to other biotech companies that need to manage limited resources.
- The company's cash runway into the second quarter of 2026 is a positive sign, but it will need to raise additional capital to continue operations beyond that point, which is typical for development-stage biotech companies.
- The company's reliance on third-party manufacturers is standard practice in the industry, but it also introduces supply chain risks.
- The company's focus on rare diseases is a common strategy for smaller biotech companies, as it can lead to orphan drug designation and market exclusivity.
- The company's Phase 3 trial for GTX-104 is a critical step, and its success will be crucial for the company's future. This is a common milestone for companies in the clinical stage of drug development.
- The company's reported net loss is typical for a development-stage biotech company, as they often do not generate revenue until their products are approved and commercialized.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Medical Officer | Dr. R. Loch Macdonald | 2023-05-08 | Strategic realignment | |
| VP Clinical Operations | Carrie DAndrea | 2023-05-08 | Strategic realignment | |
| VP Program Management | Amresh Kumar | 2023-05-08 | Strategic realignment |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Change in Certifying Accountant | The Audit Committee recommended the dismissal of Ernst & Young LLP and the engagement of KPMG LLP as the new independent registered public accounting firm. | 2023-12-11 | The change was recommended after a competitive review process and other business factors. |
| Reverse Stock Split | The Board of Directors approved an amendment to the Corporation's Articles of Incorporation to implement a reverse stock split of the Corporation's Common Shares, at a ratio of 1-for-6. | 2023-07-10 | The reverse stock split was implemented to regain compliance with the Nasdaq minimum bid price requirement. |
Legal Proceedings
- The Corporation is at times subject to various legal proceedings and disputes in the ordinary course of business.
- The Corporation assesses its liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available.
- The Corporation believes that it has established appropriate legal reserves and that any incremental liabilities arising from pending legal proceedings are not expected to have a material adverse effect on the Corporation's financial position, results of operations, or cash flows.
Related Party Transactions
- Shore Pharma LLC, an entity controlled by Vimal Kavuru, the Chair of the Board of Directors, and SS Pharma LLC, the beneficial owner of 5.5% of the Common Shares outstanding prior to the Offering, each a related party of the Corporation, participated in the private placement offering.
Stakeholder Impact
- Shareholders: The strategic realignment and focus on GTX-104 may lead to increased shareholder value if the drug is successful. The company's need for additional capital may result in dilution.
- Employees: The restructuring resulted in a reduction in workforce, impacting employees. The new management team may bring new opportunities.
- Customers: The development of GTX-104 may provide a new treatment option for aSAH patients, potentially improving clinical outcomes.
- Suppliers: The company's reliance on third-party manufacturers and CROs may impact these stakeholders.
- Creditors: The company's financial position and ability to meet its obligations are dependent on its ability to raise additional capital.
Next Steps
- The company will continue to advance the Phase 3 clinical trial for GTX-104.
- The company will evaluate strategic alternatives to maximize the value of GTX-102 and GTX-101.
- The company plans to hold a pre-NDA meeting with the FDA before submitting an NDA for GTX-104.
- The company plans to raise additional capital to maintain adequate liquidity.
Key Dates
| Date | Description |
|---|---|
| 2018-05-09 | Warrants issued pursuant to the Corporation's May 2018 Canadian public offering expired. |
| 2019-10-25 | The Corporation signed a supply agreement with Aker BioMarine Antarctic AS for raw krill oil. |
| 2020-06-29 | The Corporation entered into an amended and restated sales agreement for its ATM program. |
| 2021-08 | The Corporation completed the acquisition of Grace Therapeutics, Inc. |
| 2022-03-14 | The Corporation renewed its lease agreement for its research and development facility. |
| 2022-05-18 | Final results from the pivotal PK trial for GTX-104 were reported. |
| 2022-12-23 | Topline results from the single dose PK trial for GTX-101 were reported. |
| 2022-12-28 | Topline results of the PK bridging trial for GTX-102 were reported. |
| 2023-03-27 | The Corporation's Common Shares were no longer listed on the TSXV. |
| 2023-05-08 | The Corporation announced a strategic realignment plan and the submission of the GTX-104 Phase 3 safety study protocol to the FDA. |
| 2023-06-29 | The Board of Directors approved an amendment to the Corporation's Articles of Incorporation to implement a reverse stock split. |
| 2023-07-04 | The Corporation filed Articles of Amendment to implement the Reverse Stock Split. |
| 2023-07-05 | The Corporation announced alignment with the FDA on its GTX-104 pivotal Phase 3 safety trial protocol. |
| 2023-07-10 | The Reverse Stock Split became effective. |
| 2023-07-14 | The Corporation's Board of Directors approved the grant of options to purchase 446,502 Common Shares. |
| 2023-07-24 | The Corporation received written notice from Nasdaq that it had regained compliance with the minimum bid price requirement. |
| 2023-09-24 | The Corporation entered into a securities purchase agreement for a private placement. |
| 2023-09-25 | The private placement offering closed. |
| 2023-10-18 | The Corporation entered into a settlement agreement with AKBM. |
| 2023-10-23 | The first patient was enrolled in the STRIVE-ON clinical trial for GTX-104. |
| 2023-12-11 | The Audit Committee recommended the dismissal of Ernst & Young LLP and the engagement of KPMG LLP as the new independent registered public accounting firm. |
| 2023-12-19 | The Corporation's Board of Directors approved the grant of options to purchase 161,168 Common Shares. |
| 2024-03-31 | The Corporation's lease agreement is expected to terminate. |
Keywords
GTX-104, nimodipine, aSAH, clinical trial, pharmaceutical, drug development, biotechnology, private placement, research and development, rare diseases
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.